A Comprehensive Review of Analytical Methods Developed for Selective Serotonin Reuptake Inhibitors (SSRIs)

Ansari   Mahzabin   Safdarali; Lalit   Lata   Jha; Lakshamanbhai   Dungarbhai   Patel
Abstract

Selective Serotonin Reuptake Inhibitors (SSRIs) are a key development in psychological pharmacology and treatment. It has been demonstrated that serotonin (5-HT) has a pharmacological role in a variety of anxiety- and mood-related conditions. Fluvoxamine, citalopram, escitalopram, paroxetine, sertraline, and fluoxetine are the six primary SSRIs now available in the United States for the treatment of depression and anxiety or mood-related disorders. Despite having a different chemical structure, these compounds function in an analogous fashion. The main mechanism by which SSRIs work is by preventing serotonin from being reabsorbed presynaptically at the serotonin transporter, which raises serotonin at the postsynaptic membrane, which is found in the serotonergic synapse. In order to ensure the effectiveness, safety, and quality control of SSRIs in pharmaceutical formulations, it is crucial to quantify them precisely. The present article provides an overview of the main analytical techniques developed to evaluate SSRIs in different matrices. It covers both conventional and hyphenated approaches and concentrates on the analytical methodologies developed to quantify SSRIs. It offers a general overview of the methods that have been developed and standardized for the evaluation of SSRIs in drug formulations and various matrices. It focuses on the major components of SSRI analysis, such as the solvents used for analysis, chromatographic column selections, detection wavelength, and validation parameters. It also discusses various validation parameters, such as accuracy, precision, retention duration, maximum absorbance wavelength (λmax), range, limit of detection (LOD), and limit of quantitation (LOQ).
Keywords: Selective serotonin reuptake inhibitors, analytical method development, limit of detection (LOD), limit of quantitation (LOQ), depression, citalopram, escitalopram, fluvoxamine.
Graphical Abstract

[1]
Edinoff, A.N.; Akuly, H.A.; Hanna, T.A.; Ochoa, C.O.; Patti, S.J.; Ghaffar, Y.A.; Kaye, A.D.; Viswanath, O.; Urits, I.; Boyer, A.G.; Cornett, E.M.; Kaye, A.M. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol. Int.,  2021, 13(3), 387-401.
 [http://dx.doi.org/10.3390/neurolint13030038] [PMID:  34449705]

[2]
Greenberg, P.E.; Fournier, A.A.; Sisitsky, T.; Pike, C.T.; Kessler, R.C. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry,  2015, 76(2), 155-162.
 [http://dx.doi.org/10.4088/JCP.14m09298] [PMID:  25742202]

[3]
Yang, H.; Chuzi, S.; Sinicropi-Yao, L.; Johnson, D.; Chen, Y.; Clain, A.; Baer, L.; McGrath, P.J.; Stewart, J.W.; Fava, M.; Papakostas, G.I. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur. Arch. Psychiatry Clin. Neurosci.,  2010, 260(2), 145-150.
 [http://dx.doi.org/10.1007/s00406-009-0031-3] [PMID:  19572158]

[4]
Clevenger, S.S.; Malhotra, D.; Dang, J.; Vanle, B.; IsHak, W.W. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder. Ther. Adv. Psychopharmacol.,  2018, 8(1), 49-58.
 [http://dx.doi.org/10.1177/2045125317737264] [PMID:  29344343]

[5]
Kuhn, R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry,  1958, 115(5), 459-464.
 [http://dx.doi.org/10.1176/ajp.115.5.459] [PMID:  13583250]

[6]
Edwards, J.G.; Anderson, I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs,  1999, 57(4), 507-533.
 [http://dx.doi.org/10.2165/00003495-199957040-00005] [PMID:  10235690]

[7]
Chu, A.; Wadhwa, R. Selective Serotonin Reuptake Inhibitors. In: StatPearls; StatPearls Publishing: Treasure Island, FL, 2023. 

[8]
David, D.J.; Gourion, D. Antidepressant and tolerance: Determinants and management of major side effects. Encephale,  2016, 42(6), 553-561.
 [http://dx.doi.org/10.1016/j.encep.2016.05.006] [PMID:  27423475]

[9]
Xue, W.; Wang, P.; Li, B.; Li, Y.; Xu, X.; Yang, F.; Yao, X.; Chen, Y.Z.; Xu, F.; Zhu, F. Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. Phys. Chem. Chem. Phys.,  2016, 18(4), 3260-3271.
 [http://dx.doi.org/10.1039/C5CP05771J] [PMID:  26745505]

[10]
Rao, N. The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet.,  2007, 46(4), 281-290.
 [http://dx.doi.org/10.2165/00003088-200746040-00002] [PMID:  17375980]

[11]
DeVane, C.L. Pharmacokinetics of the selective serotonin reuptake inhibitors. J. Clin. Psychiatry,  1992, 53(Suppl.), 13-20.
 [PMID:  1531816]

[12]
Hema, S.R. A review on new analytical method development and validation by RP-HPLC. Int Res J Pharm Biosci.,  2017, 4, 41-50.

[13]
Ravisankar, P.; Navya, C.N.; Pravallika, D.; Sri, D.N. A review on step-by-step analytical method validation. IOSR J. Pharm.,  2015, 5(10), 7-19.

[14]
Siddiqui, M.R.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem.,  2017, 10, S1409-S1421.
 [http://dx.doi.org/10.1016/j.arabjc.2013.04.016]

[15]
Singh, J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J. Pharmacol. Pharmacother.,  2015, 6(3), 185-187.
 [http://dx.doi.org/10.4103/0976-500X.162004] [PMID:  26312010]

[16]
CFR - Code of Federal Regulations Title 21. 2008. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm (accessed on 2-7-2024)

[17]
EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. 2001. Available from: https://health.ec.europa.eu/document/download/7c6c5b3c-4902-46ea-b7ab-7608682fb68d_en?filename=2015-10_annex15.pdf (accessed on 2-7-2024)

[18]
McDowall, R. Practical and Effective Risk Management for Computerized System Validation. Qual. Assur. J.,  2005, 9(3), 196-227.
 [http://dx.doi.org/10.1002/qaj.339]

[19]
Bansal, S.K.; Layloff, T.; Bush, E.D.; Hamilton, M.; Hankinson, E.A.; Landy, J.S.; Lowes, S.; Nasr, M.M.; St Jean, P.A.; Shah, V.P. Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach. AAPS PharmSciTech,  2004, 5(1), E22.
 [PMID:  15198541]

[20]
Bedson, P.; Sargent, M. The development and application of guidance on equipment qualification of analytical instruments. Accredit. Qual. Assur.,  1996, 1(6), 265-274.
 [http://dx.doi.org/10.1007/s007690050083]

[21]
McPolin, O. Validation of analytical methods for pharmaceutical analysis; Lulu.com, 2009.

[22]
Guidance for Industry; Analytical Procedures and Method Validation, Chemistry, Manufacturing, and Controls Documentation. 2000. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics(accessed on 2-7-2024)

[23]
International Conference on Harmonization (1994) Validation of analytical procedures: text and methodology Q2 (R1). 1994. Available from: https://www.ema.europa.eu/en/documents/scientificguideline/ich-guideline-q2r1-validation-analytical-procedurestext-methodology-step-5-first-version_en.pdf (accessed on 2-7-2024)

[24]

The United States pharmacopeia 25. The national formulary 20: official from January 1, 2002; United States Pharmacopeial Convention: Rockville, MD, 2002. 

[25]
Saravanan, C.; Thamizhmozhi, M.; Kumar, C.S.; Sudhakar, C.; Rajesh, B.; Kumar, G.S. A novel and rapid HPTLC method for the analysis of citalopram hydrobromide in tablet dosage form–development and validation. Int. J. Adv. Sci. Res.,  2012, 3(01), 62-64.

[26]
Geryk, R.; Vozka, J.; Kalíková, K.; Tesařová, E. HPLC method for chiral separation and quantification of antidepressant citalopram and its precursor citadiol. Chromatographia,  2013, 76(9-10), 483-489.
 [http://dx.doi.org/10.1007/s10337-013-2426-6]

[27]
Hegstad, S.; Havnen, H.; Helland, A.; Falch, B.M.H.; Spigset, O. Enantiomeric separation and quantification of citalopram in serum by ultra-high performance supercritical fluid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2017, 1061-1062, 103-109.
 [http://dx.doi.org/10.1016/j.jchromb.2017.07.009] [PMID:  28715684]

[28]
Menegola, J.; Steppe, M.; Schapoval, E.E.S. Development and validation of column high-performance liquid chromatographic and ultraviolet spectrophotometric methods for citalopram in tablets. J. AOAC Int.,  2008, 91(1), 52-58.
 [http://dx.doi.org/10.1093/jaoac/91.1.52] [PMID:  18376585]

[29]
Raza, A. Development and application of spectrophotometric methods for the determination of citalopram hydrobromide in dosage forms. Chem. Pharm. Bull. (Tokyo),  2006, 54(4), 432-434.
 [http://dx.doi.org/10.1248/cpb.54.432] [PMID:  16595940]

[30]
Nageswara Rao, R.; Narasa Raju, A.; Nagaraju, D. Development and validation of a liquid chromatographic method for determination of enantiomeric purity of citalopram in bulk drugs and pharmaceuticals. J. Pharm. Biomed. Anal.,  2006, 41(1), 280-285.
 [http://dx.doi.org/10.1016/j.jpba.2005.10.025] [PMID:  16321492]

[31]
Bala, I.; Verma, S.; Haque, A.; Singh, B. Determination of acceptable residual limit by using newly developed and validated RP-HPLC method for citalopram hydrobromide residues that swabbed from surfaces of pharmaceutical manufacturing equipment. International Journal of Drug Delivery Technology,  2019, 9(1), 10-14.
 [http://dx.doi.org/10.25258/ijddt.9.1.2]

[32]
El-Gindy, A.; Emara, S.; Mesbah, M.K.; Hadad, G.M. Liquid chromatography determination of citalopram enantiomers using beta-cyclodextrin as a chiral mobile phase additive. J. AOAC Int.,  2006, 89(1), 65-70.
 [PMID:  16512230]

[33]
Bagheri, H.; Khalilian, F.; Babanezhad, E.; Es-haghi, A.; Rouini, M.R. Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. Anal. Chim. Acta,  2008, 610(2), 211-216.
 [http://dx.doi.org/10.1016/j.aca.2008.01.047] [PMID:  18291131]

[34]
Cao, X.Q.; Chen, X.Y.; Zhang, Y.F.; Zhong, D.F. [Determination of citalopram in human plasma with LC-MS/MS method and its bioequivalent evaluation]. Yao Xue Xue Bao,  2007, 42(4), 450-454.
 [PMID:  17633218]

[35]
Haupt, D. Determination of citalopram enantiomers in human plasma by liquid chromatographic separation on a Chiral-AGP column. J. Chromatogr., Biomed. Appl.,  1996, 685(2), 299-305.
 [http://dx.doi.org/10.1016/S0378-4347(96)00177-6] [PMID:  8953171]

[36]
Ramu, B. Method Development and Validation for the Determination of Citalopram Hbr by HPLC method in bulk drug and pharmaceutical dosage form. Pharm. Anal. Acta,  2017, 8(536), 2.

[37]
Rahman, A.; Haque, M.R.; Rahman, M.M.; Rashid, M.A. Development and validation of a chiral HPLC method for quantitative analysis of enantiomeric escitalopram. Dhaka University Journal of Pharmaceutical Sciences,  2018, 16(2), 165-172.
 [http://dx.doi.org/10.3329/dujps.v16i2.35253]

[38]
Vaghela, B.K.; Rao, S.S. Development and validation of stability indicating RP-LC, short runtime method for the estimation of escitalopram in escitalopram dosage form. World J. Pharm. Res.,  2013, 2, 1018-1030.

[39]
Mahadik, M.V.; Dhaneshwar, S.R.; Kulkarni, M.J. Application Of Stability Indicating HPTLC method for quantitative determination of Escitalopram Oxalate in pharmaceutical dosage form. Eurasian Journal of Analytical Chemistry.,  2007, 2(2)

[40]
Dhaneshwar, S.R.; Mahadik, M.V.; Kulkarni, M.J. Column liquid chromatography-ultraviolet and column liquid chromatography/mass spectrometry evaluation of stress degradation behavior of escitalopram oxalate. J. AOAC Int.,  2009, 92(1), 138-147.
 [http://dx.doi.org/10.1093/jaoac/92.1.138] [PMID:  19382571]

[41]
Sungthong, B.; Jáč, P.; Scriba, G.K.E. Development and validation of a capillary electrophoresis method for the simultaneous determination of impurities of escitalopram including the R-enantiomer. J. Pharm. Biomed. Anal.,  2008, 46(5), 959-965.
 [http://dx.doi.org/10.1016/j.jpba.2007.05.029] [PMID:  17629435]

[42]
Deepthi, V. Bioanalytical Method Development and Validation for the Estimation of Escitalopram Oxalate in Human Plasma by Using RP-HPLC Method.,. Doctoral dissertation, KMCH College of Pharmacy, Coimbatore. 

[43]
Sharma, S.; Rajpurohit, H.; Bhandari, A.; Choudhary, V.R.; Jain, T.; Sonwal, C. Zero order spectrophotometric method for estimation of escitalopram oxalate in tablet formulations. J. Young Pharm.,  2010, 2(4), 420-423.
 [http://dx.doi.org/10.4103/0975-1483.71626] [PMID:  21264107]

[44]
Samanta, T.; Dey, S.; Samal, H.B.; Kumar, D.B.; Mohanty, D.L.; Bhar, K. RPHPLC method for the estimation of escitalopram in bulk and in dosage forms. Int. J. Chem. Res.,  2011, 2011, 11-15.

[45]
Suneetha, A.; Sundar, B.S. A validated UV spectrophotometric method for estimation of Escitalopram Oxalate in bulk and pharmaceutical dosage forms. Asian J. Res. Chem,  2010, 3(4), 935-937.

[46]
Revathi, S.; Rahaman, S.; Prathyusha, V.; Maheswari, G.; Neeharika, M. Development and validation of UV spectrophotometric method for the estimation of fluvoxamine maleate in bulk and pharmaceutical dosage form. Indo Am. J. Pharm. Res.,  2013, 3, 6373-6380.

[47]
Darwish, I.A.; Amer, S.M.; Abdine, H.H.; Al-Rayes, L.I. Spectrofluorimetric determination of fluvoxamine in dosage forms and plasma via derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. J. Fluoresc.,  2009, 19(3), 463-471.
 [http://dx.doi.org/10.1007/s10895-008-0433-z] [PMID:  18949539]

[48]
Gupta, K.R. Force degradation study and RP-HPLC method development for estimation of fluvoxamine maleate in tablet. Int. J. Pharm. Pharm. Sci.,  2015, 7(6), 196-202.

[49]
Souri, E.; Donyayi, H.; Khaniha, R.A.; Barazandeh Tehrani, M. A stability indicating HPLC method for the determination of fluvoxamine in pharmaceutical dosage forms. Iran. J. Pharm. Res.,  2015, 14(4), 1059-1065.
 [PMID:  26664372]

[50]
Ulu, S.T. Determination and validation of an LC method for fluvoxamine in tablets. Chromatographia,  2006, 64(3-4), 169-173.
 [http://dx.doi.org/10.1365/s10337-006-0016-6]

[51]
Ulu, S.T. HPLC method for the determination of fluvoxamine in human plasma and urine for application to pharmacokinetic studies. J. Pharm. Biomed. Anal.,  2007, 43(4), 1444-1451.
 [http://dx.doi.org/10.1016/j.jpba.2006.11.005] [PMID:  17157470]

[52]
Abu-hassan, A.A.; Omar, M.A.; Derayea, S.M. Use of acetylacetone for nano‐level assay of fluvoxamine maleate in pure form and pharmaceutical formulation. Luminescence,  2020, 35(8), 1360-1365.
 [http://dx.doi.org/10.1002/bio.3898] [PMID:  32519373]

[53]
Nouws, H.P.A.; Delerue-Matos, C.; Barros, A.A.; Rodrigues, J.A.; Santos-Silva, A. Electroanalytical study of fluvoxamine. Anal. Bioanal. Chem.,  2005, 382(7), 1662-1668.
 [http://dx.doi.org/10.1007/s00216-005-3310-5] [PMID:  15983767]

[54]
Darwish, I.A.; Amer, S.M.; Abdine, H.H.; Al-Rayes, L.I. New spectrophotometric and fluorimetric methods for determination of fluoxetine in pharmaceutical formulations. Int. J. Anal. Chem.,  2009, 2009, 257306.
 [http://dx.doi.org/10.1155/2009/257306]

[55]
Vimalakkannan, T.; Reddy, K.R.; Naveena, P. Development and validation of new analytical method for the estimation of fluoxetine in bulk and dosage form by UV spectrophotometry. International Journal of Research in Pharmaceutical Chemistry and Analysis.,  2019, 1(2), 36-39.
 [http://dx.doi.org/10.33974/ijrpca.v1i2.54]

[56]
El-dawy, M.A.; Mabrouk, M.M.; El-Barbary, F.A. Liquid chromatographic determination of fluoxetine. J. Pharm. Biomed. Anal.,  2002, 30(3), 561-571.
 [http://dx.doi.org/10.1016/S0731-7085(02)00312-6] [PMID:  12367681]

[57]
Hess, M.; Höfner, G.; Wanner, K.T. Development and validation of a rapid LC-ESI-MS/MS method for quantification of fluoxetine and its application to MS binding assays. Anal. Bioanal. Chem.,  2011, 400(10), 3505-3515.
 [http://dx.doi.org/10.1007/s00216-011-4997-0] [PMID:  21516443]

[58]
Mukhopadhyay, A.; Pradhan, K.K.; Samanta, R. Development and validation of an UV-spectrophotometric method for the estimation of fluoxetine in pure and tablet dosage forms. Int. J. Pharm. Sci. Res.,  2014, 5(8), 3418.

[59]
Khan, M.F.; Ahmad, I.; Ullah, Z.; Khan, M.I.; Alahmar, A.K. Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. J. Adv. Pharm. Technol. Res.,  2021, 12(3), 267-273.
 [http://dx.doi.org/10.4103/japtr.JAPTR_308_20] [PMID:  34345606]

[60]
Kumar, A.; Jain, S.K. Development and validation of uv-spectroscopy based stability indicating method for the determination of fluoxetine hydrochloride. Anal. Chem. Lett.,  2016, 6(6), 894-902.
 [http://dx.doi.org/10.1080/22297928.2016.1278180]

[61]
Queiroz, M.E.C.; Oliveira, E.B.; Breton, F.; Pawliszyn, J. Immunoaffinity in-tube solid phase microextraction coupled with liquid chromatography–mass spectrometry for analysis of fluoxetine in serum samples. J. Chromatogr. A,  2007, 1174(1-2), 72-77.
 [http://dx.doi.org/10.1016/j.chroma.2007.09.026] [PMID:  17936291]

[62]
Rodríguez Flores, J.; Barzas Nevado, J.J.; Contento Salcedo, A.M.; Cabello Díaz, M.P. Development and validation method for determination of Paroxetine and its metabolites by nonaqueous capillary electrophoresis in human urine. Experimental design for evaluating the ruggedness of the method. Electrophoresis,  2004, 25(3), 454-462.
 [http://dx.doi.org/10.1002/elps.200305686] [PMID:  14760637]

[63]
Vergi-Athanasiou, N.; Atta-Politou, J.; Koupparis, M.; Spyropoulos, J. Development and validation of an HPLC method, with fluorescence detection, for simultaneous determination of paroxetine and its metabolites in plasma. J. Liq. Chromatogr. Relat. Technol.,  2007, 30(11), 1641-1655.
 [http://dx.doi.org/10.1080/10826070701224853]

[64]
Shah, H.J.; Kundlik, M.L.; Kakad, A.; Patel, N.K.; Pandya, A.; Khatri, V.; Prajapati, S.; Subbaiah, G.; Patel, C.N. Quantification of paroxetine in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J. AOAC Int.,  2010, 93(1), 141-149.
 [http://dx.doi.org/10.1093/jaoac/93.1.141] [PMID:  20334176]

[65]
Önal, A.; Öztunç, A. Determination of paroxetine in human plasma by high-performance liquid chromatography using 7,7,8,8-tetracyanoquinodimethane as the derivatization reagent. Ther. Drug Monit.,  2006, 28(2), 180-184.
 [http://dx.doi.org/10.1097/01.ftd.0000185768.36878.49] [PMID:  16628128]

[66]
Sankar, PR.; Roja, C.; Rahul, KS.; Pravallika, D.; Babu, PS.; Rani, KA. Development and validation of rapid RP-HPLC method for the determination of Paroxetine in bulk and pharmaceutical dosage form. Schol. Res. Libr.,  8(3), 43-52.

[67]
Sharma, M.C.; Sharma, S.M. Validated simultaneous spectrophotometric estimation of paroxetine HCL bulk and tablet dosage form using ferric chloride. J. Optoelectro. Biomed. Mater.,  2010, 2, 185-189.

[68]
Darwish, I.A.; Abdine, H.H.; Amer, S.M.; Al-Rayes, L.I. Simple spectrophotometric method for determination of paroxetine in tablets using 1,2-naphthoquinone-4-sulphonate as a chromogenic reagent. Int. J. Anal. Chem.,  2009, 2009, 1-8.
 [http://dx.doi.org/10.1155/2009/237601] [PMID:  20107559]

[69]
Janga, R.B.; Jala, S. Analytical method development and Validation for the estimation of paroxetine hydrochloride by UV Spectrophotometry and RP-HPLC in its pharmaceutical dosage form. World J. Pharmaceut. Res.,  2020, 9(8), 2309-2321.

[70]
Ferretti, R.; Gallinella, B.; La Torre, F.; Turchetto, L. Validated chiral high-performance liquid chromatographic method for the determination of trans-(−)-paroxetine and its enantiomer in bulk and pharmaceutical formulations. J. Chromatogr., Biomed. Appl.,  1998, 710(1-2), 157-164.
 [http://dx.doi.org/10.1016/S0378-4347(98)00098-X] [PMID:  9686883]

[71]
Agrawal, N.; Esteve-Romero, J.; Dubey, N.P.; Durgbanshi, A.; Bose, D.; Peris Vicente, J.; Carda-Broch, S. Determination of paroxetine in pharmaceutical preparations using HPLC with electrochemical detection. Open Analyt. Chem. J.,  2013, 7, 1-5.
 [http://dx.doi.org/10.2174/1874065001307010001]

[72]
Knoeller, J.; Vogt-Schenkel, R.; Brett, M.A. A simple and robust HPLC method for the determination of paroxetine in human plasma. J. Pharm. Biomed. Anal.,  1995, 13(4-5), 635-638.
 [http://dx.doi.org/10.1016/0731-7085(95)01315-C] [PMID:  9696579]

[73]
Lambropoulos, J.; Spanos, G.A.; Lazaridis, N.V. Method development and validation for the HPLC assay (potency and related substances) for 20 mg paroxetine tablets. J. Pharm. Biomed. Anal.,  1999, 19(5), 793-802.
 [http://dx.doi.org/10.1016/S0731-7085(98)00309-4] [PMID:  10698543]

[74]
Naidong, W.; Eerkes, A. Development and validation of a hydrophilic interaction liquid chromatography–tandem mass spectrometric method for the analysis of paroxetine in human plasma. Biomed. Chromatogr.,  2004, 18(1), 28-36.
 [http://dx.doi.org/10.1002/bmc.288] [PMID:  14872546]

[75]
Nouws, H.P.A.; Delerue-Matos, C.; Barros, A.A.; Rodrigues, J.A. Electroanalytical determination of paroxetine in pharmaceuticals. J. Pharm. Biomed. Anal.,  2006, 42(3), 341-346.
 [http://dx.doi.org/10.1016/j.jpba.2006.04.015] [PMID:  16765014]

[76]
Marella, V.; Lalitha, K.; Pravallika, M.; Nalluri, B.N. Novel RP-HPLC Method for the Determination of Paroxetine in Pure Form and in Tablet Formulation. Pharm. Methods,  2017, 9(1), 45-48.
 [http://dx.doi.org/10.5530/phm.2018.1.9]

[77]
Massaroti, P.; Cassiano, N.M.; Duarte, L.F.; Campos, D.R.; Marchioretto, M.A.; Bernasconi, G.; Calafatti, S.; Barros, F.A.; Meurer, E.C.; Pedrazzoli, J. Validation of a selective method for determination of paroxetine in human plasma by LC-MS/MS. J. Pharm. Pharm. Sci.,  2005, 8(2), 340-347.
 [PMID:  16124946]

[78]
Venkatachalam, A.; Chatterjee, V.S. Stability-indicating high performance thin layer chromatography determination of Paroxetine hydrochloride in bulk drug and pharmaceutical formulations. Anal. Chim. Acta,  2007, 598(2), 312-317.
 [http://dx.doi.org/10.1016/j.aca.2007.07.014] [PMID:  17719907]

[79]
Walsh, M.; Belal, F.; El-Enany, N.; Elmansi, H. Spectrofluorimetric Determination of Paroxetine HCl in Pharmaceuticals via Derivatization with 4-chloro-7- nitrobenzo-2-oxa-1,3-diazole (NBD-Cl). J. Fluoresc.,  2011, 21(1), 105-112.
 [http://dx.doi.org/10.1007/s10895-010-0693-2] [PMID:  20593227]

[80]
He, L.; Feng, F.; Wu, J. Determination of sertraline in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry and method validation. J. Chromatogr. Sci.,  2005, 43(10), 532-535.
 [http://dx.doi.org/10.1093/chromsci/43.10.532] [PMID:  16438795]

[81]
Zhang, M.; Gao, F.; Cui, X.; Zhang, Y.; Sun, Y.; Gu, J.; Sun, Y. Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies. J. Chromatogr. Sci.,  2011, 49(2), 89-93.
 [http://dx.doi.org/10.1093/chrsci/49.2.89] [PMID:  21223631]

[82]
Walash, M.I.; Belal, F.F.; El-Enany, N.M.; Elmansi, H. Development and validation of stability indicating method for determination of sertraline following ICH guidlines and its determination in pharmaceuticals and biological fluids. Chem. Cent. J.,  2011, 5(1), 61.
 [http://dx.doi.org/10.1186/1752-153X-5-61] [PMID:  21996025]

[83]
Venugopal, K.; Murali Krishna, N.V.; Ragalatha, P.; Mounika, T. Analytical method development and validation of sertraline in pure form by using uv spectrophotometry. World J. Pharmaceut. Res.,  2017, 6(4), 1594-1603.

[84]
Bairagi, S.H.; Ghosh, R.S. Development and Validation of RP-HPLC method for the determination of sertraline in bulk drug and dosage form. World J. Pharm. Res.,  2020, 9, 1236-1246.

[85]
Chen, D.; Jiang, S.; Chen, Y.; Hu, Y. HPLC determination of sertraline in bulk drug, tablets and capsules using hydroxypropyl-β-cyclodextrin as mobile phase additive. J. Pharm. Biomed. Anal.,  2004, 34(1), 239-245.
 [http://dx.doi.org/10.1016/j.japna.2003.08.013] [PMID:  14738940]

[86]
Chen, X.; Duan, X.; Dai, X.; Zhong, D. Development and validation of a liquid chromatographic/tandem mass spectrometric method for the determination of sertraline in human plasma. Rapid Commun. Mass Spectrom.,  2006, 20(16), 2483-2489.
 [http://dx.doi.org/10.1002/rcm.2610] [PMID:  16862624]

[87]
Ferrarini, A.; Huidobro, A.L.; Pellati, F.; Barbas, C. Development and validation of a HPLC method for the determination of sertraline and three non-chiral related impurities. J. Pharm. Biomed. Anal.,  2010, 53(2), 122-129.
 [http://dx.doi.org/10.1016/j.jpba.2010.01.036] [PMID:  20138727]

[88]
Hussain, A.; Rahman, M.A.; Hussain, M.S.; Mirza, M.A.; Iqbal, Z.; Harwansh, R.; Singh, L.R. HPTLC method for analysis of sertraline in pure bulk drug and lipidic nano delivery system: a stress degradation studies. J. Liq. Chromatogr. Relat. Technol.,  2013, 36(6), 700-716.
 [http://dx.doi.org/10.1080/10826076.2012.673208]

[89]
Jain, D.S.; Sanyal, M.; Subbaiah, G.; Pande, U.C.; Shrivastav, P. Rapid and sensitive method for the determination of sertraline in human plasma using liquid chromatography–tandem mass spectrometry (LC–MS/MS). J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2005, 829(1-2), 69-74.
 [http://dx.doi.org/10.1016/j.jchromb.2005.09.035] [PMID:  16233994]

[90]
Khraiwesh, A.; Papoutsis, I.; Nikolaou, P.; Pistos, C.; Spiliopoulou, C.; Athanaselis, S. Development and validation of an EI-GC/MS method for the determination of sertraline and its major metabolite desmethyl-sertraline in blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2011, 879(25), 2576-2582.
 [http://dx.doi.org/10.1016/j.jchromb.2011.07.015] [PMID:  21813341]

[91]
Al-Nimry, S.S.; Jaber, M.A. Development and Validation of an HPLC-UV Method for Determination of Sertraline Hydrochloride and Application to Study Dissolution of Tablets. Lat. Am. J. Pharm.,  2017, 36(4), 665-672.

[92]
Mandrioli, R.; Saracino, M.A.; Ferrari, S.; Berardi, D.; Kenndler, E.; Raggi, M.A. HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2006, 836(1-2), 116-119.
 [http://dx.doi.org/10.1016/j.jchromb.2006.03.026] [PMID:  16581317]

[93]
Chaudhari, V.; Patil, S.; Patil, M.S.; Pawar, S. Development and validation of RP-UHPLC method for determination of sertraline in bulk drug and dosage form. J. Anal. Bioanal. Tech.,  2022, 13(7), 469.

[94]
Mee Kim, K.; Hwa Jung, B.; Ho Choi, M.; Soo Woo, J.; Paeng, K.J.; Chul Chung, B. Rapid and sensitive determination of sertraline in human plasma using gas chromatography–mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.,  2002, 769(2), 333-339.
 [http://dx.doi.org/10.1016/S1570-0232(02)00027-2] [PMID:  11996499]

[95]
Ratnia, R.; Yadav, V.; Kumar, A. Method Development and Its Validation for Estimation of Sertraline Hydrochloride by Using UV Spectroscopy. Int. J. Pharma Res. Health Sci.,  2015, 3, 616-620.

[96]
Rahman, M.A.; Hussain, A.; Iqbal, Z.; Mirza, M.A. Estimation of sertraline by chromatographic (HPLC-UV273 nm) technique under hydrolytic stress conditions. Pharm. Methods,  2012, 3(2), 62-67.
 [http://dx.doi.org/10.4103/2229-4708.103874] [PMID:  23781480]

[97]
Rosetti, A.; Ferretti, R.; Zanitti, L.; Casulli, A.; Villani, C.; Cirilli, R. Single-run reversed-phase HPLC method for determining sertraline content, enantiomeric purity, and related substances in drug substance and finished product. J. Pharm. Anal.,  2020, 10(6), 610-616.
 [http://dx.doi.org/10.1016/j.jpha.2020.11.002] [PMID:  33425455]

[98]
Vadlamudi, G.A. A novel validated UV spectrophotometric method for quantitative analysis of vilazodone in pharmaceutical dosage form. Der Pharmacia. Lettre,  2014, 6(5), 296-300.

[99]
Redasani, V.K.; Sancay, J.S. Development and Validation of Vilazodone Hcl by Rp-Hplc in bulk and in pharmaceutical formulation along with its application in dissolution. Int. J. Anayt. Techniq.,  2017, 3(1), 1-7.

[100]
Agrawal, N.; Mittal, A. Ultrafast Bioanalytical Assay for Vilazodone Quantification in Human Plasma Using Vilazodone D8 Internal Standard by Uplc- Ms/ms. Research Square, 05 Dec 2022.

[101]
Yadav, N.; Goyal, A. A validated spectrophotometric method for determination of Vilazodone Hydrochloride in pharmaceutical dosage form. Int. J. Curr. Pharm. Res.,  2016, 9(1), 132.
 [http://dx.doi.org/10.22159/ijcpr.2017v9i1.16637]

[102]
Iqbal, M.; Ezzeldin, E.; Al-Rashood, K.A.; Bajrai, A.A. A simple and fast UHPLC-MS-MS assay for rapid determination of vilazodone in plasma sample. J. Anal. Toxicol.,  2015, 39(2), 106-112.
 [http://dx.doi.org/10.1093/jat/bku126] [PMID:  25404657]

[103]
El-Bagary, R.; Hashem, H.; Fouad, M.; Tarek, S. UPLC–MS-MS method for the determination of Vilazodone in human plasma: application to a pharmacokinetic study. J. Chromatogr. Sci.,  2016, 54(8), 1365-1372.
 [http://dx.doi.org/10.1093/chromsci/bmw084] [PMID:  27209054]

[104]
Panda, S.S.; Ravi Kumar, V.V.B.; Beg, S.; Sahu, S.K.; Muni, S. Development and validation of a stability-indicating liquid chromatographic method for estimating vilazodone hydrochloride in pharmaceutical dosage form using quality by design. J. Chromatogr. Sci.,  2016, 54(10), 1713-1722.
 [http://dx.doi.org/10.1093/chromsci/bmw127] [PMID:  27601040]

[105]
Mazi, C.; Karaderi, S.; Arioz, F. Determination of UV-Vis spectrophotometric method of metal complexes stoichiometry between Cu (II) and Zn (II) with vilazodone hydrochloride. Int. J. Pharmaceut. Res. Allied Sci.,  2018, 7(3), 146-152.

[106]
Fekry, A.M.; Mohamed, G.G.; Abou Attia, F.M.; Ibrahim, N.S.; Azab, S.M. A nanoparticle modified carbon paste sensor for electrochemical determination of the antidepressant agent vilazodone. J. Electroanal. Chem. ,  2019, 848, 113305.
 [http://dx.doi.org/10.1016/j.jelechem.2019.113305]

[107]
Devi, G.R.; Saravanan, G.; Yunoos, M.; Krishna, M.S. A simple validated UV spectrophotometric method for the estimation of Vilazodone hydrochloride in pure and marketed formulation. Indian J. Res. Pharm. Biotechnol.,  2017, 5(2), 164-167.

[108]
Redasani, V.K.; Chhajed, C.F.; Patil, P.D.; Surana, S.J. Development and validation of spectroscopic methods for the estimation of Vilazodone in bulk and in tablet formulation. J. Pharm. Res.,  2014, 13(1), 20-22.
 [http://dx.doi.org/10.18579/jpcrkc/2014/13/1/78404]

[109]
Kualiti, M.P. Spectrophotometric quantification of Vilazodone hydrochloride in pharmaceutical dosage form using quality by design approach. Malays. J. Anal. Sci.,  2015, 19(5), 920.

[110]
Ravisankar, P.; Gowthami, S.; Devadasu, C.H.; Srinivasa Babu, P.; Venkateswar Reddy, P. A Novel Validated RP HPLC Method for the Estimation of Vilazodone in Bulk and Pharmaceutical Dosage Form. Am. J. PharmTech Res.,  2014, 4(5)

[111]
Ghosh, S.; Venkatesh, S.; Ravikumar, B.V. Development of stability indicating RP-HPLC method and validation for the estimation of vilazodone hydrochloride. Int. J. Pharm. Tech. Res.,  2015, 7, 204-211.
Cite As
Current Pharmaceutical Analysis

A Comprehensive Review of Analytical Methods Developed for Selective Serotonin Reuptake Inhibitors (SSRIs)

Abstract

Graphical Abstract
